Off-label prescribing linked with higher rates of adverse drug events Doctors should be cautious about prescribing off-label drugs unless they have strong evidence to support their decision, study concludes.…
FDA approves opioid Oxycontin for adolescents The US Food and Drug Administration has approved the use of the opioid OxyContin (oxycodone) for children aged 11–16 years whose pain is severe enough to require daily around-the-clock long-term treatment for which alternative options are inadequate.…
Orthostatic hypotension drug midodrine to be launched Midodrine hydrochloride (Bramox) is due to be launched in the UK on 29 July 2015 after obtaining marketing authorisation from the medicines safety regulator, its manufacturer has announced.…
Report highlights extent of inappropriate prescribing in adults with learning disabilities One in six adults with learning disabilities but no diagnosis of mental illness are being prescribed antipsychotic drugs by a GP, according to a new report.…
Clinigen acquires unlicensed medicine supplier Idis in £225m dealThe UK company Clinigen has acquired its rival Idis in a £225m deal, which it says will make it the market-leader in the $5bn global unlicensed pharmaceuticals supply market.…
Saatchi bill defeated at emotionally charged HealthWatch UK debate The Medical Innovation Bill is unnecessary and should not become law, according to medical professionals and lawyers who gathered for a HealthWatch UK debate.…
Skin cancer drug fast tracked under early access to medicines schemeA drug for advanced skin cancer, pembrolizumab, has become the first medicine to be fast tracked to patients under the UK’s early access to medicines scheme.…
Treating mental health disorders in children and adolescents ‘Clinical handbook of psychotropic drugs for children and adolescents 3rd edition’ by Elbe D, Bezchlibnyk-Butler K Z, Virani A S , Procyshyn R M.…
Smart drugs worth £200,000 seized in the UKA haul of “smart drugs” with a street value of £200,000 has been seized in the UK. …
Off-label macular degeneration therapy has similar safety to costly licensed drug, study finds Bevacizumab is similarly safe to use for the treatment of neovascular age-related macular degeneration (AMD) as the more expensive ranibizumab, but has a risk of causing gastrointestinal disorders, a Cochrane review has found.…
